research Protein Degradation: Expanding the Toolbox to Restrain Cancer Drug Resistance
Using protein degradation to fight cancer drug resistance shows promise but needs more precise targeting and fewer side effects.
Search
forLearn
0 / 0 results — no results
Research
5 / 119 results 
research Comparative Gene Expression Profiling of Senescent and Androgenetic Alopecia Using Microarray Analysis
SA linked to mitochondrial issues and oxidative stress, while AGA involves disrupted hair growth genes.
research Transcriptome Profiling of Human Follicle Dermal Papilla Cells in Response to Porphyra-334 Treatment by RNA-Seq
Porphyra-334 may help reduce wrinkles and promote hair growth.
research The JAK/STAT Signaling Pathway: From Bench to Clinic
The JAK/STAT pathway is important in cell processes and disease, and JAK inhibitors are promising for treating related conditions.
research Xenobiotic-Metabolizing Enzymes in the Skin of Rat, Mouse, Pig, Guinea Pig, Man, and in Human Skin Models
Different species and human skin models vary in their skin enzyme activities, with pig skin and some models closely matching human skin, useful for safety assessments and understanding the skin's protective roles.
Community Join
2 / 2 resultscommunity PYRILUTAMIDE PHASE 3 RESULTS : No statistical significance
by
HMI115_GIGACHAD
in Research/Science
126 upvotes
1 year ago The phase 3 trial results for Pyrilutamide showed no significant difference from the control treatment in increasing hair count, leading to the company halting its development. Users discussed their disappointment and skepticism about hair loss treatments, with some mentioning other treatments like Minoxidil, Finasteride, and RU58841.
community GT20029 China Phase II Trial For AGA Reached Primary Endpoint
by
Synizs
in Research/Science
134 upvotes
9 months ago The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.